French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis’s recently approved Kymriah, has been forced to suspend testing following a patient death.
LONDON (Reuters) – French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis&rsquo-s recently approved Kymriah, has been forced to suspend testing following a patient death.
Cellectis said on Tuesday it was working closely with the U.S. Food and Drug Administration, which placed a so-called clinical hold on its product, in order to resume trials with a lower dose of the medicine UCART123.
0 comments
Share
